Category: News
-
Once Valued At Around $7B, Cancer Blood Test Developer Grail To Kickstart Trading On NASDAQ
in NewsNearly four years after first pitching for Grail Inc. (NASDAQ:GRAL), Illumina Inc. (NASDAQ:ILMN) announced Monday that it would spin off the cancer blood test developer. In July 2021, Illumina said it was committed to re-acquiring Grail. Starting today, 25 June, Grail will begin trading the “regular way” under its own Nasdaq ticker, GRAL, as an independent…